Provided by Tiger Trade Technology Pte. Ltd.

ResMed

226.73
+0.75000.33%
Pre-market: 226.730.00000.00%04:12 EDT
Volume:651.15K
Turnover:147.02M
Market Cap:31.97B
PE:21.74
High:226.88
Open:225.79
Low:223.04
Close:225.98
52wk High:284.05
52wk Low:180.27
Shares:141.00M
Float Shares:140.00M
Volume Ratio:0.66
T/O Rate:0.47%
Dividend:2.40
Dividend Rate:1.06%
EPS(TTM):10.43
EPS(LYR):10.43
ROE:24.27%
ROA:14.00%
PB:4.85
PE(LYR):21.74

Loading ...

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Eli Lilly & Co (LLY)

TIPRANKS
·
Jul 13

RMD or the 4% Rule? One Lets You Live Large and not Run Out of Money.

Dow Jones
·
Jul 11

Resmed is Maintained at Hold by Jefferies

Dow Jones
·
Jul 11

ResMed price target lowered to $225 from $240 at Jefferies

TIPRANKS
·
Jul 10

Jefferies Adjusts Price Target on ResMed to $225 From $240

MT Newswires Live
·
Jul 10

ResMed CEO Farrell Exercises Options and Trims Stake Under 10b5-1 Plan

TIPRANKS
·
Jul 10

Resmed Inc-statement of Changes in Beneficial Ownership

THOMSON REUTERS
·
Jul 10

Statement of Changes in Beneficial Ownership-rmd.n

Reuters
·
Jul 10

ResMed (RMD) After Russell Growth Index Exits Is The Undervalued Narrative Still Intact

Simply Wall St.
·
Jul 10

Nyxoah: Orin Hirchman-controlled Entities Disclose 14.55% Stake, Crossing 10% Threshold

Reuters
·
Jul 10

Resmed CEO Michael Farrell Sells 4,991 Shares for $1.09 Million

Reuters
·
Jul 09

Jarden Adjusts ResMed's Price Target to AU$40.20 from AU$42.70, Keeps at Overweight

MT Newswires Live
·
Jul 09

ResMed's Sale of MatrixCare Shows Willingness to Recycle Capital From Rationalizing Underperforming Units, Jarden Says

MT Newswires Live
·
Jul 09

Resmed Willing to Cut Underperforming Assets

Dow Jones
·
Jul 09

Resmed's $490M Sale Looks Strategically Sound

Dow Jones
·
Jul 09

ResMed: MatrixCare Divestiture Sharpens SaaS Growth Outlook, Supports Attractive Valuation and Reiterated Buy Rating

TIPRANKS
·
Jul 09

ResMed's $490 Million Sale of MatrixCare Not Material to Outlook, RBC Says

MT Newswires Live
·
Jul 08

Analysts Offer Insights on Healthcare Companies: Resmed (RMD) and Prime Medicine, Inc. (PRME)

TIPRANKS
·
Jul 08

Movement Alert|ResMed Falls 5.29% in Regular Trading, MatrixCare Divestiture Announcement Coupled with RBC Price Target Cut

Market Focus
·
Jul 08

RBC Capital Cuts ResMed Price Target to $276 From $321, Maintains Outperform Rating

MT Newswires Live
·
Jul 08